Levodopa medications in the treatment of Parkinson's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 5, 2011, Pages 30-36

  Fedorova, N V ^a   Yablonskaya, A Yu ^a   Belgusheva, M E ^a  

^a NONE

Author keywords

Levodopa; Nakom; Parkinson's disease

Indexed keywords

LEVODOPA; RASAGILINE;

ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; PARKINSON DISEASE; UNIFIED PARKINSON DISEASE RATING SCALE; CATALEPSY; DISEASE SEVERITY; DYSKINESIA; MONOTHERAPY; NEUROPROTECTION; SPEECH DISORDER;

EID: 80052483563     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Russian Source.
2. Russian Source.
3. O'Sullivan S.S., Evans A.H., Lees A.J. Dopamine dysregulation syndrome. An overview of its epidemiology, mechanisms and management. CNS Drugs 2009; 23: 2: 157-170.
4. Caspar P., Duyckaens C. et al. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurology 1991; 30: 365-374.
5. Clarke C.E., Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 5: 590-594.
6. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000; 55: 1621-1626.
7. Fahn S., Eiton R. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disearse. Eds. Fahn S., Marsden C., Calne D. et al. McMillan Healthcare Information 1987; 5: 153-163.
8. Fan S., Oakes D., Shoulson I. et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
9. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State: a practical guide for grading the mental state of patients for the clinician. J Psychiat Res 1975; 12: 189-198.
10. Hoehn M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
11. Hoehn M.M. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992; 10: 2: 331-339.
12. Koller W.C., Tse W. Unmet medical needs in Parkinson's disease. Neurology 2004; 62: 17-22.
13. Kummer A., Maia D.P., Salgado J.V. et al. Dopamine dysregulation syndrome in Parkinson's disease: case report. Arq Neuropsiquiatr 2006; 64: 4: 1019-1022.
14. Kurlan R. «Levodopa phobia». A new iatrogenic cause of disability in Parkinson's disease. Neurology 2005; 64: 5: 923-924.
15. Markham C.H., Diamond S.G. Evidence to support early levodopa therapy in Parkinson's disease. Neurology 1981; 31: 125-131.
16. Nutt J.G., Wooten G.F. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005; 353: 10: 1021-1027.
17. Olanow C.W., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998; 50: 3: 27-30.
18. Olanov C.W., Agid Y., Mizuno Y. et al. Levodopa in the treatment of Parkinson's disease: curent controversies. Mov Disord 2004; 19: 9: 997.
19. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998; 51: 25-29.
20. Rajput A.H. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism and related disorders 2001; 8: 95-100.
21. Rajput A.H., Fenton M.E., Birdi S. et al. Clinical-patological study of levodopa complications. Mov Dis 2002; 17: 289-296
22. Stacy M. et al. Wearing-off Questionnaire. Clinical Neuropharmacology 2006; 26: 6: 312-321.